Plasma proteins predict conversion to dementia from prodromal disease - Wikidata - wikimedia - TriplyDB

Plasma proteins predict conversion to dementia from prodromal disease

Plasma proteins predict conversion to dementia from prodromal disease

http://www.wikidata.org/entity/Q34556953

about

The dual roles of cytokines in Alzheimer's disease: update on interleukins, TNF-α, TGF-β and IFN-γ Expanding the Repertoire of Biomarkers for Alzheimer's Disease: Targeted and Non-targeted Approaches Blood-Based Proteomic Biomarkers of Alzheimer's Disease Pathology Ageing, neurodegeneration and brain rejuvenation The influence of insulin resistance on cerebrospinal fluid and plasma biomarkers of Alzheimer's pathology Introducing Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, an open access journal of the Alzheimer's Association Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline.Altered levels of blood proteins in Alzheimer's disease longitudinal study: Results from Australian Imaging Biomarkers Lifestyle Study of Ageing cohort.The Alzheimer's Prevention Clinic at Weill Cornell Medical College / New York - Presbyterian Hospital: Risk Stratification and Personalized Early Intervention.Blood biomarkers for Alzheimer's disease.Intravenously injected human apolipoprotein A-I rapidly enters the central nervous system via the choroid plexus.Upregulation of glycolytic enzymes, mitochondrial dysfunction and increased cytotoxicity in glial cells treated with Alzheimer's disease plasma.Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis.Antiphospholipid autoantibodies as blood biomarkers for detection of early stage Alzheimer's disease Two-sample tests and one-way MANOVA for multivariate biomarker data with nondetects.Central Nervous System and Peripheral Inflammatory Processes in Alzheimer's Disease: Biomarker Profiling Approach.A novel multi-tissue RNA diagnostic of healthy ageing relates to cognitive health status.The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations Abnormalities of plasma cytokines and spleen in senile APP/PS1/Tau transgenic mouse model.Protein signature in cerebrospinal fluid and serum of Alzheimer's disease patients: The case of apolipoprotein A-1 proteoforms.Immunocapture strategies in translational proteomics.CFH Variants Affect Structural and Functional Brain Changes and Genetic Risk of Alzheimer's Disease.A Late Life Risk Index for Severe Cognitive Impairment in Mexico.Blood protein predictors of brain amyloid for enrichment in clinical trials?A semi-mechanism approach based on MRI and proteomics for prediction of conversion from mild cognitive impairment to Alzheimer's disease Potential fluid biomarkers for pathological brain changes in Alzheimer's disease: Implication for the screening of cognitive frailty.Combined Plasma and Cerebrospinal Fluid Signature for the Prediction of Midterm Progression From Mild Cognitive Impairment to Alzheimer Disease The Role of Clinical Proteomics, Lipidomics, and Genomics in the Diagnosis of Alzheimer's Disease.Influence of CFH gene on symptom severity of schizophrenia.Recent advances in biomarkers for Parkinson's disease focusing on biochemicals, omics and neuroimaging.Schizophrenia biomarkers: translating the descriptive into the diagnostic.Biomarkers in Sporadic and Familial Alzheimer's Disease.The Role of Visinin-Like Protein-1 in the Pathophysiology of Alzheimer's Disease.Biochemical and Radiological Markers of Alzheimer's Disease Progression.Plasma REST: a novel candidate biomarker of Alzheimer's disease is modified by psychological intervention in an at-risk population Attitudes to Alzheimer's disease testing of Australian general practice patients: a cross-sectional questionnaire-based study.Neutral polymers as coatings for high resolution electrophoretic separation of Aβ peptides on glass microchips.Alzheimer's Disease: Biomarkers in the Genome, Blood, and Cerebrospinal Fluid.Apolipoprotein E genotypes and plasma levels in mild cognitive impairment conversion to Alzheimer's disease: A follow-up study.Complement Biomarkers as Predictors of Disease Progression in Alzheimer's Disease.

P2860

Q26750987-12B65B93-4490-45A3-8C1A-9184816A522B Q26770708-6A980F2C-E888-4BE8-800C-EF8BA6A2AE1E Q26774743-8D191FCA-FD12-4AE8-BCE5-21B761ABB2FC Q28071590-7D040EF1-EEEA-4E1E-A013-B65B4945C983 Q29994562-7B7395E1-7E8A-4D98-BD5B-5BFF2408F23E Q30489394-14D8D0E4-B2AF-483C-ADC3-2D1443FC3F36 Q30996727-41D67C64-6557-49B2-B273-3EED2A45882E Q33652456-158E1EF9-C699-44DF-8437-23D04DCFF146 Q33697647-C2C7D65D-3FE0-477A-963D-2489D9DBE14C Q34624763-A0963AAD-CDAB-4CFB-B2C6-194AB12F90B7 Q35114943-9C55750B-7607-4668-8EF1-C6163F5EA64C Q35191570-039196A6-24E0-44FC-BE50-FA8F3C8247A9 Q35686186-58245CCB-FE0C-4086-BB16-36087073473C Q35812498-19DEDF11-053C-4D67-A6DF-98F279BBB5D6 Q35964938-013713DD-FBB0-4C53-83E4-D18B9ABB1D65 Q35990600-CE74338D-EDF4-4A2F-A17D-C50FBBCBC62E Q36032418-DFAF0D4A-7A3E-40A2-8793-F7C13AB16CFC Q36165011-B1941A39-6EB3-4912-A8F0-73F7E00C209D Q36209842-9673DA31-B3A5-4661-B510-D69F245E7132 Q36409186-25376FA0-55CC-40BB-B00C-5B891BB4BF4B Q36519000-1199E3F7-4BEA-49EA-B435-812A3C48911E Q36565635-63C67F6E-EB3D-4FA7-B839-F73E23C14896 Q36855363-6D2C7944-8504-411D-801B-67CAD7A05B8B Q36926754-A09CC848-2495-4521-8842-6971D05DD714 Q36976353-BC6C7BFD-B596-480A-85CE-DE9FB11DC3C1 Q37297626-45ECD483-77E9-48A9-A827-ABF0A00A2B8A Q37559815-9EAF1C2C-F7F8-4CC7-BFAC-34E3B4154B61 Q37566373-8435090F-0048-42E3-8DFD-A598743DC961 Q37688663-E0C3B8B0-6217-473F-8D37-8F0C42EA22DC Q38315590-8F4D33A0-0B58-4C7C-8043-7031D21DEAEE Q38324251-B7F021CE-5568-446A-92CE-A583853E616B Q38592041-4D5EE046-D260-40CF-A50A-272C11237E90 Q38592265-3DF0DE0F-6C66-4C23-979F-4F95F2B06A45 Q38693438-F14D6426-D623-42F2-95B4-2722FD2C016F Q38741096-55624E0F-7F0F-4D4E-95ED-10A08BC66C61 Q38975863-6CC5665E-2CF3-4329-8C37-FE98C76A1AF8 Q39106083-E07E2777-21DC-4908-9D70-B8A6CB0765E8 Q39217840-E32D1BEE-A88A-4725-A8FD-4A49937F6650 Q39412788-40D4BE8E-BDB6-4710-A347-C19F9EF88BBA Q39447009-0408AA34-489B-4974-8751-84A1C003E983

P2860

Plasma proteins predict conversion to dementia from prodromal disease

http://www.wikidata.org/entity/Q34556953

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Plasma proteins predict conversion to dementia from prodromal disease

@ast

Plasma proteins predict conversion to dementia from prodromal disease

@en

Plasma proteins predict conversion to dementia from prodromal disease

@nl

type

label

Plasma proteins predict conversion to dementia from prodromal disease

@ast

Plasma proteins predict conversion to dementia from prodromal disease

@en

Plasma proteins predict conversion to dementia from prodromal disease

@nl

prefLabel

Plasma proteins predict conversion to dementia from prodromal disease

@ast

Plasma proteins predict conversion to dementia from prodromal disease

@en

Plasma proteins predict conversion to dementia from prodromal disease

@nl

P1433

Q34556953-C89910F6-7EC3-4B80-AAC0-BE34F31CE218

P1476

Q34556953-A7374409-7D71-4359-9BAA-E692ADF4BDD6

P2093

Q34556953-14632557-1203-4DAA-A44B-A6C4A750DF8B

Q34556953-1495CD74-1871-4838-9C6C-62C3D883F2E3

Q34556953-2F129427-7D10-470D-A786-888178D800AA

Q34556953-30B9DC23-7DFB-449A-878A-0D4097A42024

Q34556953-3A15EB24-AE3F-4AAF-BC5A-116206815693

Q34556953-41E47CD3-9827-4828-A9ED-A446AE2770BA

Q34556953-42F48502-D9BF-4E0A-86A5-83882F950592

Q34556953-4AAF8074-DFA8-46D1-ACA6-7F159C043C49

Q34556953-5EF4B276-CB33-4272-AE96-AB6461A2C479

Q34556953-6A2277D2-287D-4550-83D3-84EECA15DA77

P2860

Q34556953-0ADE074E-E412-4AF8-B46B-6D6EF6DB85EE

Q34556953-0B2749D5-AE06-4861-852A-94F9B072471D

Q34556953-0D71BC84-C408-4751-9CED-DD8F9FA2EB67

Q34556953-1B93CE45-E199-4F4B-8A69-2DB5DA8F8C86

Q34556953-206BB8FD-B4CB-4DC1-B419-9C28ABA391AD

Q34556953-23B68CAD-AF6D-45CA-B161-89F4FB7E53E9

Q34556953-24AD725E-4C12-4B62-AE72-912F016EA022

Q34556953-2605028B-9BD2-4F9A-862E-92B9E04004B7

Q34556953-2ED116A7-C7EB-4F40-887E-EA1F8F46238F

Q34556953-40195D53-5EA5-4320-9D23-1A275C0EDEE8

P304

Q34556953-82FA4164-EEAB-467D-BAD9-F8544DD176A7

P31

Q34556953-9F372C6A-18DD-4A61-A47F-A6A1C2640C9A

P356

Q34556953-B75A337F-852B-4986-BC2B-D4C76EC09E65

P433

Q34556953-A3997EE0-F7B1-4000-A0D0-35CE4445E679

P478

Q34556953-5F0AAE4D-90F3-4B3D-9BC4-42675C9ED841

P50

Q34556953-1C51AB19-C99A-45FF-B1D0-6362B1BE1415

Q34556953-25D0018B-BD37-4B99-B3FC-A22E7446F4B7

Q34556953-3B1E60DA-E87C-4449-B2FD-5BE06BBCCDEA

Q34556953-43319A7C-D05E-4972-A8E7-D323AF5707E0

Q34556953-54B03EFE-DC20-4563-837A-ACC1AE909D5C

Q34556953-60ABDC89-9B92-47D5-A1EF-D73B6EE85522

Q34556953-7BC21A73-E82F-4162-94C1-AA951C4F44AF

Q34556953-9F74B061-5155-4FE0-890A-BB90D85DF89C

Q34556953-B6510372-3862-4AAE-BA26-812B4426B7E7

Q34556953-B824FAA7-5F3E-48B3-8A88-EBEC09DC2095

P577

Q34556953-F184A88E-E9D2-42B8-879C-77F5CFC970D5

P5875

Q34556953-AF530DE3-09A6-4371-A31D-13048D6B2428

P698

Q34556953-15955545-852C-47E8-89D4-94A9C9E88748

P921

Q34556953-D15BF318-E46C-4DF3-87BC-E10D6DC69F14

P932

Q34556953-84B19879-B9A9-46D7-955B-339279581956

P356

J.JALZ.2014.05.1749

P1433

Alzheimer's and Dementia

P1476

Plasma proteins predict conversion to dementia from prodromal disease

@en

P2093

Alan Tunnicliffe

http://www.w3.org/2001/XMLSchema#string

Alison L Baird

http://www.w3.org/2001/XMLSchema#string

Andrew Simmons

http://www.w3.org/2001/XMLSchema#string

Chantal Bazenet

http://www.w3.org/2001/XMLSchema#string

Danielle Pepin

http://www.w3.org/2001/XMLSchema#string

Hans Dieter Zucht

http://www.w3.org/2001/XMLSchema#string

Ian Pike

http://www.w3.org/2001/XMLSchema#string

Jill Richardson

http://www.w3.org/2001/XMLSchema#string

Joanna Riddoch-Contreras

http://www.w3.org/2001/XMLSchema#string

Martina Sattlecker

http://www.w3.org/2001/XMLSchema#string

P2860

The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods.

Mild cognitive impairment: clinical characterization and outcome

Plasma biomarkers of brain atrophy in Alzheimer's disease

A blood-based screening tool for Alzheimer's disease that spans serum and plasma: findings from TARC and ADNI

Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease

RANTES upregulation in the Alzheimer's disease brain: a possible neuroprotective role.

Multivariate analysis of MRI data for Alzheimer's disease, mild cognitive impairment and healthy controls.

Serum levels of S100B and NSE proteins in Alzheimer's disease patients

Overexpression of human apolipoprotein A-I preserves cognitive function and attenuates neuroinflammation and cerebral amyloid angiopathy in a mouse model of Alzheimer disease.

Plasma based markers of [11C] PiB-PET brain amyloid burden.

P304

799-807.e2

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JALZ.2014.05.1749

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

Simon Lovestone

Iwona Kłoszewska

Hilkka Soininen

Patrizia Mecocci

Michelle K Lupton

P577

2014-07-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263736910

http://www.w3.org/2001/XMLSchema#string

P698

25012867

http://www.w3.org/2001/XMLSchema#string

P921

P932

4240530

http://www.w3.org/2001/XMLSchema#string